video

Source: NY1

NEW YORK – Researchers at NYU’s Grossman School of Medicine found patients given the antimalarial drug hydroxychloroquine along with zinc sulphate and the antibiotic azithromycin were 44 percent less likely to die from the coronavirus.

“Certainly we have very limited options as far as what we have seen work for this infection so anything that may work is very exciting,” said Dr. Joseph Rahimian, Infectious Disease Specialist at NYU Langone Health.

The study looked at the records of 932 COVID-19 patients treated at local hospitals with hydroxychloroquine and azithromycin.

More than 400 of them were also given 100 milligrams of zinc daily. 

Researchers said the patients given zinc were one and a half times more likely to recover, decreasing their need for intensive care.

One theory is that hydroxychloroquine may aid a cell’s ability to absorb the zinc which has antiviral properties and responds to the infection.

“It sort of boosts the zinc activity which is one of the reasons we thought to look at zinc here and in this observational study we did see a difference suggesting that maybe that boosting activity of the hydroxychloroquine with the zinc helps the zinc to work better and lead to a benefit,” Rahimian said.

Dr. Rahimian says patients in the more critical stages of infection did not fare as well.

And he cautioned that more research is needed – in particular a randomized controlled trial – to prove how and how well the drug combination works.

Read the original article here: https://www.ny1.com/nyc/all-boroughs/news/2020/05/12/nyu-study-looks-at-hydroxychloroquine-zinc-azithromycin-combo-on-decreasing-covid-19-deaths

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »